Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimiralisib - PIQUR Therapeutics

Next Previous
Drug Profile

Bimiralisib - PIQUR Therapeutics

Alternative Names: PQR-309

Latest Information Update: 25 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PIQUR Therapeutics
  • Class Amines; Antineoplastics; Antipsoriatics; Eye disorder therapies; Fluorinated hydrocarbons; Morpholines; Pyridines; Skin disorder therapies; Small molecules; Triazines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Head and neck cancer; Lymphoma; Plaque psoriasis
  • Phase I/II Breast cancer
  • No development reported Brain disorders; Eye disorders; Skin cancer; Skin disorders; Solid tumours

Most Recent Events

  • 25 Jan 2022 PIQUR Therapeutics terminates a phase II trial in Head and neck cancer (Recurrent, Metastatic disease) (PO) in USA because the sponsor became insolvent (NCT03740100)
  • 28 Mar 2021 No recent reports of development identified for preclinical development in Skin-cancer in Switzerland (Topical)
  • 28 Mar 2021 No recent reports of development identified for preclinical development in Skin-disorders in Switzerland (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top